文献速递乳腺癌

BRCA突变携带者的OncotypeDX复发评分:系统综述与荟萃分析

OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2021-07-17

该系统综述与荟萃分析纳入5项回顾性队列研究共4286例ER+/HER2-早期乳腺癌患者,比较BRCA突变携带者与散发病例的OncotypeDX复发评分(RS)。BRCA突变携带者平均RS为25,散发病例为18.4;散发病例更易出现RS<18,BRCA突变携带者更易出现RS 18-30和RS>30。

要点

  • BRCA突变携带者ER+/HER2-早期乳腺癌的OncotypeDX复发评分整体高于散发病例。
  • 散发病例出现RS<18的几率更高,BRCA突变携带者出现RS 18-30和RS>30的几率更高。
  • 该结果或有助于未来BRCA突变患者的咨询。

核心结论

  • 已知胚系BRCA突变的ER+/HER2-早期乳腺癌患者相比散发病例,具有更高风险RS的可能性增加。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA和MOOSE指南,纳入比较BRCA突变携带者与散发病例RS的回顾性队列研究。
  • 共纳入5项研究、4286例患者,平均年龄60岁(范围22-85),BRCA突变携带者占7.8%(333/4286)。

主要发现

  • 总体平均RS为18.0(范围0-71),BRCA携带者平均RS为25(范围10-71),散发病例为18.4(范围0-62)。
  • 散发病例更易出现RS<18(OR 0.27,95%CI 0.14-0.51,P=0.010)。
  • BRCA突变携带者更易出现RS 18-30(OR 1.74,95%CI 1.28-2.37,P<0.001)。
  • BRCA突变携带者更易出现RS>30(OR 3.71,95%CI 2.55-5.40,P<0.001)。

临床怎么用

  • 对于已知胚系BRCA突变的ER+/HER2-早期乳腺癌患者,OncotypeDX复发评分可能更高,可辅助未来临床咨询。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are limited data comparing the OncotypeDX© Recurrence Score (RS) among BRCA mutation carriers and patients with sporadic breast cancer. AIM: To compare RS results among BRCA mutation carriers and patients with sporadic breast cancer in oestrogen receptor positive (ER+), human epidermal growth factor receptor-2 negative (HER2-) breast cancer. METHODS: A systematic review was performed in accordance with PRISMA and MOOSE guidelines. Retrospective cohort studies comparing RS in BRCA mutation carriers and cases of sporadic cancer were included. Dichotomous variables were pooled as odds ratios (ORs) and associated 95% confidence intervals (CIs) using the Mantel-Haenszel method. RESULTS: Five studies involving 4286 patients were included with a mean age of 60 years (range 22-85). Overall, 7.8% were BRCA mutation carriers (333/4286). The mean RS was 18.0 (range 0-71), and the mean RS in BRCA carriers was 25 (range 10-71) versus 18.4 in cases of sporadic disease (range 0-62). Patients with sporadic cancers were more likely to have RS < 18 (OR 0.27, 95% CI 0.14-0.51, P = 0.010). BRCA mutation carriers were more likely to have RS 18-30 (OR 1.74, 95% CI 1.28-2.37, P < 0.001) and RS > 30 (OR 3.71, 95% CI 2.55-5.40, P < 0.001). CONCLUSION: There is an increased likelihood of high-risk RS among patients with known germline BRCA mutations when compared to patients developing sporadic ER+/HER2-early breast cancer. This study offers insight into genomic testing results within BRCA mutation carriers which may be useful in counselling patients with BRCA mutations in future practice.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Davey MG, Richard V, Lowery AJ, et al. OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis. Eur J Cancer. 2021. PMID: 34284256. doi:10.1016/j.ejca.2021.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。